Literature DB >> 21526495

Assessment of the pathway of apoptosis involving PAR-4, DAXX and ZIPK proteins in CLL patients and its relationship with the principal prognostic factors.

Agnieszka Bojarska-Junak1, Małgorzata Sieklucka, Iwona Hus, Ewa Wąsik-Szczepanek, Maria Luiza Kusz, Agata Surdacka, Sylwia Chocholska, Anna Dmoszyńska, Jacek Roliński.   

Abstract

Par-4 (prostate apoptosis response-4) protein was originally found upregulated in prostate tumor cells undergoing apoptosis. Then it was further identified as a proapoptotic protein upregulated both in normal and leukemic lymphocytes. The aim of our study was to assess PAR-4 protein expression in the B cells of CLL patients and to examine its relationship with the expression of other proteins involved in the apoptosis process, such as DAXX, ZIPK and BCL-2. We found a positive relationship between PAR-4 and BCL-2 protein expression. Additionally, there was a positive correlation between PAR-4 and both DAXX and ZIPK protein expression. The results of our research were also analyzed in association with the principal CLL prognostic factors. There was a positive correlation between the expression of PAR-4 protein and the lactate dehydrogenase (LDH) serum concentration (p < 0.005). The expression of PAR-4 protein in B cells correlated positively with the percentage of CD38(+) cells (p < 0.05), as well as with CD38(+)/ZAP-70(+) cells (p < 0.05). Moreover, we found a close relationship between LPL protein expression or LPL/ADAM29 MFI ratio and PAR-4 protein expression. Our results confirm the significance of apoptosis deregulation in CLL, and suggest a possible relationship between PAR-4 expression and the clinical course of the disease. This however requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21526495     DOI: 10.5603/fhc.2011.0014

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  2 in total

1.  Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.

Authors:  J T Greene; Rajeswaran Mani; Rahul Ramaswamy; Frank Frissora; Max Yano; Kevan Zapolnik; Bonnie Harrington; Ronni Wasmuth; Minh Tran; Xiaokui Mo; Mary McKenna; Vivek M Rangnekar; John C Byrd; Subbarao Bondada; Natarajan Muthusamy
Journal:  Blood Adv       Date:  2019-04-23

2.  Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

Authors:  Mary K McKenna; Sunil K Noothi; Sara S Alhakeem; Karine Z Oben; Joseph T Greene; Rajeswaran Mani; Kathryn L Perry; James P Collard; Jacqueline R Rivas; Gerhard C Hildebrandt; Roger A Fleischman; Eric B Durbin; John C Byrd; Chi Wang; Natarajan Muthusamy; Vivek M Rangnekar; Subbarao Bondada
Journal:  Blood       Date:  2018-04-25       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.